[HTML][HTML] PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells

L Bazzani, S Donnini, F Finetti, G Christofori, M Ziche - Oncotarget, 2017 - ncbi.nlm.nih.gov
Abstract Prostaglandin E 2 (PGE 2) interacts with tyrosine kinases receptor signaling in both
tumor and stromal cells supporting tumor progression. Here we demonstrate that in non …

[HTML][HTML] PGE2 mediates EGFR internalization and nuclear translocation via caveolin endocytosis promoting its transcriptional activity and proliferation in human …

L Bazzani, S Donnini, A Giachetti, G Christofori… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Abstract Prostaglandin E 2 (PGE 2) contributes to tumor progression by promoting cancer
cell growth, invasion and by creating a favorable pro-tumor microenvironment. PGE 2 has …

Prostaglandin E2 Activates Mitogen-Activated Protein Kinase/Erk Pathway Signaling and Cell Proliferation in Non–Small Cell Lung Cancer Cells in an Epidermal …

K Krysan, KL Reckamp, H Dalwadi, S Sharma… - Cancer research, 2005 - AACR
Abstract Cyclooxygenase 2 (COX-2) overexpression is found in a wide variety of human
cancers and is linked to all stages of tumorigenesis. Elevated tumor COX-2 expression is …

Prostaglandin E2 Promotes Lung Cancer Cell Migration via EP4-βArrestin1-c-Src Signalsome

JI Kim, V Lakshmikanthan, N Frilot, Y Daaka - Molecular Cancer Research, 2010 - AACR
Many human cancers express elevated levels of cyclooxygenase-2 (COX-2), an enzyme
responsible for the biosynthesis of prostaglandins. Available clinical data establish the …

Cooperation between prostaglandin E2 and epidermal growth factor receptor in cancer progression: A dual target for cancer therapy

F Finetti, L Paradisi, C Bernardi, M Pannini, L Trabalzini - Cancers, 2023 - mdpi.com
Simple Summary Inflammation is the biological response of the body to damaging and toxic
stimuli, and is a positive event that evolves with the resolution of critical events (acute …

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

N Sunaga, K Kaira, H Imai, K Shimizu, T Nakano… - Oncogene, 2013 - nature.com
KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer
(NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a …

EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways

S Donnini, F Finetti, R Solito, E Terzuoli… - The FASEB …, 2007 - Wiley Online Library
In squamous cell carcinoma, the levels of nitric oxide (NO) derived from inducible NO
synthase (iNOS) and prostaglandin E2 (PGE2) derived from cyclooxygenase‐2 (COX‐2) …

Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3

T Yamaki, K Endoh, M Miyahara, I Nagamine… - Cancer letters, 2004 - Elsevier
Accumulating evidence suggests that overproduction of prostaglandin (PG) E2 attributable
to induction of cyclooxygenase-2 plays an important role in the development of lung …

Epiregulin as a therapeutic target in non-small-cell lung cancer

N Sunaga, K Kaira - Lung Cancer: Targets and Therapy, 2015 - Taylor & Francis
Epiregulin (EREG) belongs to the ErbB family of ligands. EREG binds to EGFR and ErbB4
receptor and stimulates homodimers of EGFR and ErbB4 in addition to all possible …

Prostaglandin E2 promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway‐dependent induction of c‐Myc expression in human …

L Yu, WKK Wu, ZJ Li, HT Li, YC Wu… - International journal of …, 2009 - Wiley Online Library
Abstract Overexpression of cyclooxygenase‐2 (COX‐2) and elevation of its derivative
prostaglandin E2 (PGE2) are implicated in human esophageal squamous cell carcinoma …